SHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sotera Health Co (SHC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and hedge fund interest, making it a solid long-term investment despite short-term technical weakness.
The MACD is negatively expanding (-0.185), indicating bearish momentum. RSI is neutral at 21.073, and moving averages are converging, showing no clear trend. Key support is at $16.885, and resistance is at $18.421. The stock is currently trading near its support level, which could provide a potential entry point.
Analysts have upgraded the stock with a price target of $24, citing strong fundamentals, high margins, and improved end-market demand.
Hedge funds have significantly increased their buying activity by 140.83% in the last quarter.
Financial performance in Q3 2025 shows robust growth in revenue (+9.05% YoY), net income (+184.91% YoY), and EPS (+183.33% YoY).
Insiders have increased selling activity by 131.94% in the last month.
Technical indicators suggest short-term bearish momentum.
Stock trend analysis indicates a 60% chance of minor declines in the short term (-0.58% next day, -1.15% next week).
In Q3 2025, Sotera Health reported revenue of $311.31M (+9.05% YoY), net income of $48.4M (+184.91% YoY), EPS of $0.17 (+183.33% YoY), and a gross margin of 56.04% (+12.26% YoY). These figures indicate strong financial health and growth trends.
Analysts are bullish on SHC. RBC Capital resumed coverage with an Outperform rating and a $24 price target, citing strong fundamentals and high margins. Piper Sandler upgraded the stock to Overweight with a $24 price target, highlighting improved demand for its Sterigenics franchise. William Blair initiated coverage with an Outperform rating, emphasizing recurring revenue and pricing power.
